Fund managers were being offered $US150 million ($226 million) worth of shares in cancer treatment hopeful Telix Pharmaceuticals after Tuesday’s close, as JPMorgan got going on the delta placement leg of a $600 million convertible notes deal in lieu of an abandoned Nasdaq listing.
Terms sent to potential investors show Telix shares were being offered under a variable price book build at $18.60 a share to $19.60. That represented a 3.5 per cent to 8.4 per cent discount to the last close. The book was due to shut at 7:30pm.
Source - Australian Financial Review
Fund managers were being offered $US150 million ($226 million)...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.31 |
Change
0.680(3.46%) |
Mkt cap ! $6.796B | |||
| Open | High | Low | Value | Volume |
| $20.22 | $20.43 | $19.94 | $39.67M | 1.963M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100 | $20.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 29999 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| TLX (ASX) Chart |